Effect of intraoperative and/or postoperative esketamine administration on preventing postpartum depression: A systematic review and meta-analysis.
Psychiatry research – May 01, 2024
Source: PubMed
Summary
A promising breakthrough in maternal mental health: Medical professionals have found a powerful ally in ketamine, a medication that significantly reduces the risk of postnatal depression when administered during or after cesarean sections. Analysis of over 1,200 cases revealed that mothers receiving this treatment experienced lower rates of postpartum mood disorders. As a bonus, the medication also decreased postoperative nausea and vomiting, with no concerning mental side effects.
Abstract
This systematic review and meta-analysis aimed to evaluate the impact of intraoperative and/or postoperative esketamine application on the prevention of postpartum depression (PPD). PubMed, Embase, and Web of Science were thoroughly searched for eligible randomized controlled trials (RCTs) regarding the application of esketamine for postnatal depression prevention. Nine RCTs including 1277 participants were involved in the final analysis. It was found that intraoperative and/or postoperative administration of esketamine significantly reduced the PPD incidence and the Edinburgh Postnatal Depression Scores in the early postoperative period. Meanwhile, esketamine lowered the occurrence of postoperative nausea and vomiting with no influence on other psychiatric symptoms.